#Stem cell treatment of ms plus

The number of new clinical relapses following the transplant served as the primary outcome and new MRI lesions, overall survival and safety as the secondary outcomes.

#Stem cell treatment of ms plus

Busulfan plus cyclophosphamide followed by anti-thymocyte globulin post-transplant of a CD34+ selected graft composed the conditioning regimen used for aHSCT. They retrospectively studied outcomes of 72 patients with aggressive MS who received aHSCT for MS at a single center between October 2001 and February 2021 and who were monitored for at least 6 months. Specifically, Brunet and colleagues sought to examine whether autologous hematopoietic stem cell transplantation (aHSCT) led to durable disease remission and safety by analyzing short- and long-term outcomes from the Ottawa cohort. “The objective was to determine if the bone marrow transplant was effective and safe at long term,” Francis Brunet, of the MS clinic at Ottawa General Hospital in Canada, said during a presentation. Autologous hematopoietic stem cell transplantation had long-term effectiveness for treating aggressive MS, according to results of a retrospective observational study presented at the ACTRIMS Forum. If you continue to have this issue please contact to Healio